<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294914</url>
  </required_header>
  <id_info>
    <org_study_id>SJ-822</org_study_id>
    <nct_id>NCT04294914</nct_id>
  </id_info>
  <brief_title>Catastrophizing and Virtual Reality's Impact on Pain in Patients With Fibromyalgia</brief_title>
  <official_title>Catastrophizing and Virtual Reality's Impact on the Pain Threshold During a Cold Pressor Test in Patients With Fibromyalgia: A Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the potential association between Virtual Reality, pain catastrophizing
      thoughts and pain measures in fibromyalgia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Half the participants will start with intervention 1 after which they will crossover to intervention 2. The other half will start start with intervention 2 before crossing over to intervention 1.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The participants are blind to the study hypothesis and therefore the expected outcome of the tests performed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>through study completion, an average of 90minutes</time_frame>
    <description>Pain intensity during the interventions is scored using a Visual Analog Scale or Numeric Rating Scale (0 = no pain and 10 = worst known pain)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain threshold</measure>
    <time_frame>through study completion, an average of 90minutes</time_frame>
    <description>Pain threshold is defined as when the participants feel the sensation changing from an unpleasant feeling to a painful experience (measured in seconds)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain tolerance</measure>
    <time_frame>through study completion, an average of 90minutes</time_frame>
    <description>Pain tolerance is when the participants no longer are able to withstand the pain (measured in seconds).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain catastrophizing</measure>
    <time_frame>through study completion, an average of 90minutes</time_frame>
    <description>The pain catastrophizing score is measured by filling out the pain catastrophizing scale questionnaire. The pain catastrophizing scale consists of 13 sentences assessing pain-related thoughts or feelings. These are then divided into 3 domains: rumination, magnification and helplessness. The subject is asked to rate how well each sentence applies for them: 0 = not at all, 1 = to a slight degree, 2 = to a moderate degree, 3 = to a great degree and 4 = all the time.
The total score on the questionnaire can lie between 0 - 52 where a higher score indicates higher levels of pain catastrophizing thoughts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals with fibromyalgia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy, pain-free individuals</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Pressor Test</intervention_name>
    <description>The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.</description>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cold Pressor Test + Virtual Reality</intervention_name>
    <description>The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment</description>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to understand, read and speak Danish

          -  Able to independently answer a questionnaire

          -  Able to give informed consent

        Fibromyalgia group:

          -  Confirmed diagnosed with fibromyalgia

        Controls:

          -  Healthy participants

        Exclusion Criteria:

        Applies for both groups:

          -  Signs of anxiety, depression and post-traumatic stress syndrome that require treatment

          -  Neurologic, musculoskeletal or mental illnesses that could influence the results.

          -  Parallel participating in other studies, that can influence this study

          -  Pregnancy

        Fibromyalgia group:

          -  Regulation in medication

          -  Anticonvulsivant use the last week

          -  Serotonin-norepinephrine reuptake Inhibitor (SNRI) the last two weeks

          -  Tricykliske antidepressants (TCA) the last four weeks

        Controls:

          -  No regular use of pain medication

          -  No current or previous history of subacute or ongoing pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffan WM Christensen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Of Health Science and Technology, Aalborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi LA Kristensen, PBa</last_name>
    <phone>+4522716866</phone>
    <email>hlak18@student.aau.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Interdisciplinary Paincenter Naestved, Naestved hospital</name>
      <address>
        <city>Naestved</city>
        <state>Zealand</state>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Heidi LA Kristensen, Pba.</last_name>
      <phone>+4522716866</phone>
      <email>helkr@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Heidi LA Kristensen, Pba.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Vain-Nielsen, Pba.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 29, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Steffan Wittrup Christensen</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

